Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Medtronic
McKesson
Harvard Business School
Covington
UBS
Baxter
Cerilliant
US Department of Justice

Generated: May 23, 2018

DrugPatentWatch Database Preview

IRESSA Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Iressa patents expire, and what generic alternatives are available?

Iressa is a drug marketed by Astrazeneca and Astrazeneca Pharms and is included in two NDAs.

The generic ingredient in IRESSA is gefitinib. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gefitinib profile page.
Drug patent expirations by year for IRESSA
Pharmacology for IRESSA
Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Synonyms for IRESSA
(3-CHLORO-4-FLUORO-PHENYL)-[7-METHOXY-6-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-4-YL]-AMINE
(3-chloro-4-fluorophenyl)[7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl]amine
15215-EP2269994A1
15215-EP2272827A1
15215-EP2272832A1
15215-EP2275413A1
15215-EP2277865A1
15215-EP2280006A1
15215-EP2281813A1
15215-EP2281815A1
15215-EP2287156A1
15215-EP2292234A1
15215-EP2292615A1
15215-EP2298768A1
15215-EP2298778A1
15215-EP2301533A1
15215-EP2301933A1
15215-EP2305640A2
15215-EP2305671A1
15215-EP2311807A1
15215-EP2311827A1
15215-EP2311840A1
15215-EP2316832A1
15215-EP2316833A1
184475-35-2
3-Chloro-4-Fluoro-N-[(4z)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)quinazolin-4(1h)-Ylidene]aniline
32333-EP2281815A1
32333-EP2292615A1
32333-EP2301933A1
32333-EP2305640A2
32333-EP2305671A1
32333-EP2311827A1
4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)-quinazoline
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-
4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-
4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-
475G352
4CA-0562
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
A812870
AB0000095
AB01273954_04
AB01273954-01
AB01273954-02
AB01273954-03
AB20814
ABP000855
AC-1556
AC1L3X0A
AJ-74091
AK-72948
AKOS000280752
AM20090619
AMX10169
AN-5192
AOB6917
API0002810
BC215794
BCB03_000781
BCP9000718
BCPP000221
BDBM5447
Bio-0046
BR-72948
C-22438
CAS-184475-35-2
CC-28943
CCG-220642
CCRIS 9011
CG0031
CHEBI:49668
CHEMBL939
cid_123631
CJ-16232
CS-0124
CTK7A0364
CU-00000000396-1
D01977
D09XZB
DB00317
DR002765
DSSTox_CID_21034
DSSTox_GSID_41034
DSSTox_RID_79614
DTXSID8041034
EBD446
EN002708
FC0028
FT-0081035
FT-0602325
G-4408
Gefitini
Gefitini; Iressa
Gefitinib
Gefitinib - Iressa
Gefitinib (JAN/USAN/INN)
gefitinib (zd1839)
Gefitinib [USAN]
Gefitinib for system suitability, EuropePharmacopoeia (EP) Reference Standard
Gefitinib, >=98% (HPLC)
Gefitinib, EuropePharmacopoeia (EP) Reference Standard
Gefitinib, Iressa, ZD1839
Gefitinib,Iressa, ZD1839
Gefitinib,ZD-1839,Iressa
Gefitinib;
Gefitinib; Iressa
Gefitinib/ZD-1839,Iressa
GEFTINIB
GP9843
GTPL4941
H018
HE320284
HE320285
HMS2089B19
HMS3244M21
HMS3244M22
HMS3244N21
HMS3654A07
HY-50895
I01-1227
IRE
Iressa (AstraZeneca)
Iressa (TN)
Iressa(TM)
Iressa|||ZD 1839
IRRESSA
Irressat
J10250
K00240
KB-52238
KBioSS_002241
Kinome_3321
Kinome_3322
KS-00000E11
KS-1204
LS-139916
MCULE-6951584187
MFCD04307832
MLS003899193
MolPort-000-883-335
N-?(3-?CHLORO-?4-?FLUOROPHENYL)-?7-?METHOXY-?6-?[3-?(4-?MORPHOLINYL)PROPOXY]-?4-?QUINAZOLINAMINE
N-(3-chloranyl-4-fluoranyl-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NCGC00159455-04
NCGC00159455-05
NCGC00159455-06
NCGC00159455-08
NCGC00159455-09
nchembio866-comp14
NSC-715055
NSC-759856
NSC715055
NSC759856
Pharmakon1600-01502274
Q-201149
QCR-105
RS0033
S-2176
s1025
S65743JHBS
SC-18023
SCHEMBL7866
SMR002204119
SR-00000000262
SR-00000000262-2
ST2413546
STK621310
SYN1042
Tox21_111683
Tox21_111683_1
UNII-S65743JHBS
XGALLCVXEZPNRQ-UHFFFAOYSA-N
Z1551429741
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614

US Patents and Regulatory Information for IRESSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca IRESSA gefitinib TABLET;ORAL 021399-001 May 5, 2003 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms IRESSA gefitinib TABLET;ORAL 206995-001 Jul 13, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms IRESSA gefitinib TABLET;ORAL 206995-001 Jul 13, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for IRESSA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca IRESSA gefitinib TABLET;ORAL 021399-001 May 5, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca IRESSA gefitinib TABLET;ORAL 021399-001 May 5, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms IRESSA gefitinib TABLET;ORAL 206995-001 Jul 13, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca IRESSA gefitinib TABLET;ORAL 021399-001 May 5, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cipla
Daiichi Sankyo
Farmers Insurance
Teva
Accenture
Baxter
Fuji
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.